Horrigan Jamie M, Louis Edouard, Spinelli Antonino, Travis Simon, Moum Bjorn, Salwen-Deremer Jessica, Halfvarson Jonas, Panaccione Remo, Dubinsky Marla C, Munkholm Pia, Siegel Corey A
Inflammatory Bowel Disease Center, Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
Department of Gastroenterology, CHU Liège University Hospital, Liège, Belgium.
Crohns Colitis 360. 2023 Feb 22;5(2):otad006. doi: 10.1093/crocol/otad006. eCollection 2023 Apr.
Many patient-reported outcomes (PROs) have been developed for inflammatory bowel disease (IBD) without recommendations for clinical use. PROs differ from physician-reported disease activity indices; they assess patients' perceptions of their symptoms, functional status, mental health, and quality of life, among other areas. We sought to investigate the current global use and barriers to using PROs in clinical practice for IBD.
A cross-sectional survey was performed. An electronic questionnaire was sent to an international group of providers who care for patients with IBD.
There were 194 respondents, including adult/pediatric gastroenterologists, advanced practice providers, and colorectal surgeons from 5 continents. The majority (80%) use PROs in clinical practice, 65% frequently found value in routine use, and 50% frequently found PROs influenced management. Thirty-one different PROs for IBD were reportedly used. Barriers included not being familiar with PROs, not knowing how to incorporate PRO results into clinical practice, lack of electronic medical record integration, and time constraints. Most (91%) agreed it would be beneficial to have an accepted set of consistently used PROs. The majority (60%) thought that there should be some cultural differences in PROs used globally but that PROs for IBD should be consistent around the world.
PROs are used frequently in clinical practice with wide variation in which are used and how they influence management. Education about PROs and how to use and interpret an accepted set of PROs would decrease barriers for use and allow for global harmonization.
已经为炎症性肠病(IBD)开发了许多患者报告结局(PRO),但尚无临床使用的建议。PRO与医生报告的疾病活动指数不同;它们评估患者对自身症状、功能状态、心理健康和生活质量等方面的看法。我们试图调查PRO在IBD临床实践中的当前全球使用情况和使用障碍。
进行了一项横断面调查。向一组国际上照顾IBD患者的医疗服务提供者发送了电子问卷。
共有194名受访者,包括来自5个大洲的成人/儿童胃肠病学家、高级执业医疗服务提供者和结直肠外科医生。大多数(80%)在临床实践中使用PRO,65%经常在常规使用中发现其价值,50%经常发现PRO会影响治疗管理。据报告使用了31种不同的IBD的PRO。障碍包括不熟悉PRO、不知道如何将PRO结果纳入临床实践、缺乏电子病历整合以及时间限制。大多数(91%)同意有一套公认的、一致使用的PRO会有益处。大多数(60%)认为全球使用的PRO应该存在一些文化差异,但IBD的PRO在全球应该是一致的。
PRO在临床实践中被频繁使用,在使用的种类及其对治疗管理的影响方面存在很大差异。对PRO以及如何使用和解释一套公认的PRO进行教育将减少使用障碍,并实现全球统一。